Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound biopsy could replace risky lung surgery for scarred lungs

NCT ID NCT07305220

Diagnosis Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an ultrasound-guided needle biopsy is a safe way to diagnose interstitial lung disease (ILD), a group of conditions that scar the lungs. Fifteen adults who need a tissue sample will first get the ultrasound-guided biopsy under local anesthesia, then have the standard surgical biopsy. Researchers will track serious complications like collapsed lung or bleeding to see if the less invasive method is safe enough to use routinely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ultrasound-guided lung biopsy
What this could lead to
If this procedure proves safe, it could offer a less risky, outpatient alternative to surgical lung biopsy for diagnosing interstitial lung disease.
What could go wrong
This is a very small, early feasibility study with only 15 people. The procedure may still cause complications like collapsed lung or bleeding, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age 18-75 years * Diagnosed with diffuse ILD * Histological analysis required after standard diagnostic workup * Biopsy indication validated by MDD * Affiliated with French social security * Written informed consent Exclusion Criteria * Contraindication to SLB * Coagulation disorders * Significant comorbidities affecting safety * Long-term oxygen therapy * FVC \<55%, DLCO \<40% * BMI \>35 kg/m² * Pulmonary hypertension (PAPS \>40 mmHg) * Allergy to anesthetics * Protected populations (pregnant women, minors, legally protected adults) * β-HCG test required for non-menopausal women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung disease (ILD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease (ILD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pneumology department

    Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.